Article
Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for BRCA1/2.
Journal of medical genetics - 19 Apr 2024
Innella Giovanni, Ferrari Simona, Miccoli Sara, Luppi Elena, Fortuno Cristina, Parsons Michael T, Spurdle Amanda B, Turchetti Daniela
Abstract excerpt
BACKGROUND: BRCA1/2 testing is crucial to guide clinical decisions in patients with hereditary breast/ovarian cancer, but detection of variants of uncertain significance (VUSs) prevents proper management of carriers. The ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) BRCA1/2 Variant Curation Expert Panel (VCEP) has recently developed BRCA1/2 variant classification guidelines...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
